PPBT (Purple Biotech) EBITDA Margin %: 0.00% (As of Mar. 2026)


PPBT Purple Biotech Ltd PPBT
25 GF Score
Price $1.63
! 2 Warning Signs
View Full Analysis

What is Purple Biotech EBITDA Margin %?

Purple Biotech PPBT -2.98% 25 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates PPBT with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Purple Biotech ranks worse than 106157.01% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Purple Biotech's EBITDA for the three months ended in Mar. 2026 was $0.01 Mil. Purple Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Purple Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Purple Biotech  (NAS:PPBT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Purple Biotech EBITDA Margin % Related Terms

Purple Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Purple Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech EBITDA Margin % Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PPBT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Purple Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Purple Biotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Purple Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Purple Biotech's EBITDA Margin % falls into.


PPBT
25GF Score
Purple Biotech Ltd PPBT
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Purple Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-26.25/0
= %

Purple Biotech's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0.007/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Purple Biotech (PPBT) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Purple Biotech and its competitors. According to the industry distribution chart, Purple Biotech ranks #999999 out of 942 companies in the Biotechnology industry.
Is Purple Biotech's EBITDA Margin % too high?
Purple Biotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, Purple Biotech ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Purple Biotech has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Purple Biotech ranks #999999 out of 942 companies for EBITDA Margin %. This places Purple Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Purple Biotech and its competitors. Purple Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Purple Biotech's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Purple Biotech (PPBT), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
25GF Score

Get the complete analysis for PPBT

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.63
Price